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The causative agent of Chagas’ disease, Trypanosoma cruzi, affects approximately 
10 million people living mainly in Latin America, with macrophages being one of the 
first cellular actors confronting the invasion during T. cruzi infection and their function 
depending on their proper activation and polarization into distinct M1 and M2 subtypes. 
Macrophage polarization is thought to be regulated not only by cytokines and growth 
factors but also by environmental signals. The metabolic checkpoint kinase mammalian 
target of rapamycin (mTOR)-mediated sensing of environmental and metabolic cues 
influences macrophage polarization in a complex and as of yet incompletely understood 
manner. Here, we studied the role of the mTOR pathway in macrophages during T. cruzi 
infection. We demonstrated that the parasite activated mTOR, which was beneficial for 
its replication since inhibition of mTOR in macrophages by different inhibitors decreased 
parasite replication. Moreover, in rapamycin pretreated and infected macrophages, we 
observed a decreased arginase activity and expression, reduced IL-10 and increased 
interleukin-12 production, compared to control infected macrophages treated with 
DMSO. Surprisingly, we also found a reduced iNOS activity and expression in these 
macrophages. Therefore, we investigated possible alternative mechanisms involved 
in controlling parasite replication in rapamycin pretreated and infected macrophages. 
Although, cytoplasmic ROS and the enzyme indoleamine 2, 3-dioxygenase (IDO) were 
not involved, we observed a significant increase in IL-6, TNF-α, and IL-1β production. 
Taking into account that IL-1β is produced by activation of the cytoplasmic receptor 
NLRP3, which is one of the main components of the inflammasome, we evaluated 
NLRP3 expression during mTOR inhibition and T. cruzi infection. We observed that rapa-
mycin-pretreated and infected macrophages showed a significant increase in NLRP3 
expression and produced higher levels of mitochondrial ROS (mtROS) compared with 
control cells. Moreover, inhibition of mtROS production partially reversed the effect of 
rapamycin on parasite replication, with there being a significant increase in parasite load 
in rapamycin pretreated and infected macrophages from NLRP3 KO mice compared to 
wild-type control cells. Our findings strongly suggest that mTOR inhibition during T. cruzi 
infection induces NLRP3 inflammasome activation and mtROS production, resulting in 
an inflammatory-like macrophage profile that controls T. cruzi replication.
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inTrODUcTiOn
Trypanosoma cruzi, which is an intracellular protozoan parasite, 
is the etiologic agent of Chagas disease. This is a chronic con-
dition affecting in the region of 10 million people worldwide 
who mostly reside in Latin America (1). Although, many of the 
mechanisms involved in the pathogenesis of Chagas disease are 
not well understood, the development and severity of American 
trypanosomiasis depends on immune-mediated mechanisms. 
The pathogen-associated molecular patterns (PAMPs) present 
in T. cruzi can be recognized by pattern recognition receptors, 
which is a crucial event in host resistance (2), with the capability 
of T. cruzi to infect and replicate within of different cells, among 
them macrophages (3), being an critical feature in its cycle (4).
Macrophages are key effector cells that participate in dif-
ferent stages of immune responses, such as antigen presenta-
tion, phagocytosis, and the secretion of bioactive molecules. 
Macrophages may either suppress T. cruzi replication or 
afford a favorable environment where it can reproduce and be 
distributed to other area within the body (3–6). Furthermore, 
macrophages are indispensible in tissue homeostasis and have 
a significant effect on protective immunity and pathological 
immune-mediated damage (7–9). Macrophages are generally 
thought to represent a range of activated phenotypes instead of 
stable subpopulations. Normally, these are separated into two 
specific phenotypes, classically activated macrophages (M1) 
and alternatively activated ones (M2) (10–14). The M1 types are 
considered effector cells when responding to microbial prod-
ucts or interferon-gamma (IFN-γ), and are characterized by a 
large antigen presenting ability and yielding pro-inflammatory 
cytokines, including interleukin-12 (IL-12), tumor necrosis 
factor alpha (TNF-α), nitric oxide (NO), and reactive oxygen 
species (ROS) (13, 15, 16). Consequently, M1 macrophages 
stimulate a polarized type I immune response that mediates host 
defense against infections of bacteria, viruses, and protozoa as 
well as tumor cells. On the other hand, M2 macrophages are 
induced by IL-13, IL-4, glucocorticoids, and IL-10, and they 
display an anti-inflammatory function, as well as promoting 
adaptive Th2 immunity and regulating angiogenesis, wound 
healing, and tissue remodeling (11–13).
Despite it being well known that the transcriptional response 
triggered by PAMP recognition of the surrounding microenvi-
ronments (including cytokines and growth factors) determines 
the phenotype and function of macrophages (13, 15–17), the 
intrinsic molecular mechanisms driving macrophage polariza-
tion are not yet been fully understood. Related to this, macrophage 
polarization is also thought to be regulated by environmental 
signals with the metabolic checkpoint kinase mammalian target 
of rapamycin (mTOR) mediating the sensing of the environmen-
tal and metabolic cues influencing macrophage polarization in a 
complex but still incompletely understood manner (18).
The mTOR protein is a conserved serine–threonine kinase 
which is known to influence multiple cellular functions, such 
as cell growth, proliferation, and survival by integrating signals 
from nutrients, energy status, growth factors, cytokines, and 
TLRs (19, 20). These signals are recognized by the PI3-K–Akt 
axis, and depending on the context, can activate mTORC1 or 
mTORC2 complexes (20). Immediately downstream of Akt is 
the tuberous sclerosis complex (TSC), which consists of the TSC 
tumor suppressors TSC1 and TSC2, and also Tre2-TBC1D7. 
These control the Ras homolog enriched in the brain (RHEB), 
which is a crucial GTPase regulator of mTORC1. On this 
complex being phosphorylated by Akt or ERK1/2, it becomes 
inhibited and RHEB is activated, resulting in the activation of 
mTORC1 (20). In a general context, protein synthesis is the best 
characterized process controlled by mTORC1, with this kinase 
directly phosphorylating the translational regulator eukary-
otic translation initiation factor 4E (eIF4E)-binding protein1 
(4EBP1) and S6 kinase (S6K), which in turn, promote protein 
synthesis (21).
The activation of mTOR has been shown to downregulate 
IL-12p70 and IL-23 production in LPS-stimulated human 
macrophages (22). Futhermore, IL-12 was enhanced, but 
IL-10 was blocked, following mTOR inhibition in mouse bone 
marrow-derived macrophages (BMDMs) and myeloid dendritic 
cells (23). These results suggest that mTOR activation might 
limit the pro-inflammatory responses. However, other studies 
have demonstrated that TSC1-deficient macrophages produce 
certain pro-inflammatory cytokines, including TNF-α, IL-6, 
and IL-12p40 as a response to multiple TLR ligands (18, 19, 23). 
Related to this, TSC1-deficient BMDMs treated with LPS led to 
an increased pro-inflammatory cytokine production, such as 
IL-6 and TNF-α, but showed a reduction in anti-inflammatory 
cytokine IL-10 secretion (17, 24, 25). Despite the increasing 
number of investigations examining the effects of mTOR on the 
immune system, little emphasis has been placed on the function 
of this pathway in macrophages during infection.
Inflammasomes are nucleotide-binding oligomerization 
domain like receptors (NLRs) expressed on macrophages and 
acti vated in T. cruzi infection. When the inflammasome complex 
is activated, the pro-IL-1β is cleaved in an IL-1β active form 
(26, 27). In this study, we investigated the role of mTOR on 
macrophage polarization and parasite growth during T. cruzi 
infection. We demonstrated that T. cruzi can activate mTOR, with 
this molecule being important for its survival since mTOR inhibi-
tion decreased the parasite load in macrophages. We also showed 
that mTOR inhibition in T. cruzi-infected macrophages activates 
NLRP3 inflammasome, upregulates IL-12, IL-6, TNF-α, IL-1β, 
and mitochondrial ROS (mtROS), but downregulates IL-10 and 
NO production as well as reducing arginase and iNOS activity 
and expression. These results indicate that mTOR activation 
induced by the parasite may be important in inducing a M2 phe-
notype which favors parasite replication. In contrast, mTOR inhi-
bition in T. cruzi-infected macrophages induces an inflammatory 
M1-like phenotype which was able to limit parasite replication.
MaTerials anD MeThODs
Mice
The BALB/c mice used were obtained from the Comisión Nacio-
nal de Energía Atómica (Buenos Aires, Argentina). Male TNFα-
RKO (B6.129-Tnfrsf1atm1Mak), IL6KO (B6.129S2-Il6/Jtm1Copf), 
and NLRP3 KO (B6.129S6-Nlrp3/Jtm1Bhk) mice were purchased 
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from the Jackson Laboratory. Male C57BL/6J mice were from 
Universidad Nacional de La Plata (Argentina). All mice were 
inbred and housed according to institutional guidelines (28).
Trypanosoma cruzi infection
The T. cruzi infection protocols were performed as described (29). 
Briefly, the infection was maintained through intraperitoneal 
inoculations every 11 days. Then, blood-derived trypomastigotes 
were used to infect monolayers of Vero cells. After 7 days, super-
natants were collected and stored at −80°C.
BMDMs and Peritoneal Macrophages (PM)
To obtain the BMDMs, the femur and tibia bones from differ-
ent mice strains were flushed with cold RPMI 1640 containing 
40  µg/mL gentamycin, following standard procedures (30). 
These recovered bone marrow progenitor cells were cultured in 
100-mm bacteriologic plastic Petri dishes containing RPMI1640 
supplemented with 10% FBS, 40  µg/mL gentamycin, 2  mM 
l-glutamine, and 30% L929-cell-conditioned medium (31) for 
4 days. Then, bone marrow progenitors were supplemented with 
RPMI-LCM 30%. At day 6, BMDM were used as mentioned 
below, with a flow cytometric analysis of BMDM (Figure S1 in 
Supplementary Material) revealing that these cells were CD11b+ 
and F4/80+.
BALB/c mice underwent intraperitoneal infection as des-
cribed previously (29), then PM were extracted and processed 
using several techniques. Non-infected animals were processed 
in parallel as control.
chemical reagents
DMSO, LY294002, diphenyleneiodonium chloride (DPI), 
1-methyl-dl-tryptophan, ATP, Griess reagent assay, DAPI, and 
phosphatase inhibitor (PhosphoStop) were obtained from Sigma-
Aldrich (St. Louis, MO, USA); rapamycin and Fluorsave were 
purchased from Calbiochem (Darmstadt, Germany) and PP242 
from Cayman Chemical (Ann Arbor, MI, USA); Recombinant 
mouse IFNγ, anti-F4/80+ (PE) and anti-CD11b+ (APC) FACS 
antibodies, recombinant mouse IL-4, ELISA Kits Assay IL-10, 
IL-12p70, TNFα, IL-6, and IL-1β were obtained from BioLegend 
(San Diego, CA, USA); LPS (from E. coli 0111:B4 strain) was from 
InvivoGen with DAF-FM, H2DCFDA, and MitoSOX TM Red 
probes and protein ladders being obtained from Thermo Fisher 
Scientifics (Waltham, MA, USA). Western blot (WB) antibodies 
anti-phospho-mTOR, anti-phospho-p70S6K, anti-phospho-
4EBP1, anti-ATP-cytrate lyase, anti-β-actin, anti-NLRP3, and 
anti-IL-1β were acquired from Cell Signaling Technology 
(Danvers, MA, USA) and anti-Arginase I and anti-iNOS anti-
bodies were obtained from Santa Cruz Biotechnology (Palo 
Alto, CA, USA). The Odyssey antibodies IRDye® 680RD Donkey 
anti-Rabbit and IRDye® 680RD Donkey anti-Mouse IgG were 
obtained from Li-Cor Biosciences (Lincoln, NE, USA). Finally, 
antibody anti-IgGh was from Biocientifica and protease inhibitor 
cocktail from Roche (Basilea, Switzerland).
inhibitors and stimulus Treatments
Bone marrow-derived macrophage from Balb/c or C57BL6 mice 
at day 6 of differentiation were cultured for 3 h in RPMI-2%FBS 
for their adhesion. After that, cells were pretreated with DMSO 
as control; or pretreated with different inhibitors: 1-methyl-dl-
tryptophan (1-MT, 100  µM, during 24  h, 37°C); diphenylenei-
odonium chloride (DPI, 20 µM, during 3 h, 37°C), PP242 (40 or 
80 nM, for 90 min., 37°C), LY294002 (10 or 50 nM, for 90 min.), 
rapamycin (50 or 100 nM, for 90 min.). After pretreatment, the 
BMDM were washed three times and then infected with T. cruzi 
(1:5, cell:parasites ratio). In addition, BMDM without inhibitor 
pretreatment were stimulated with LPS (1 µg/mL, as positive con-
trol of mTOR activation), LPS (1 µg/mL) + IFNγ (100 ng/mL), as 
positive control of M1 polarization, IL-4 (80 ng/mL), as positive 
control of M2 polarization, LPS (1 µg/mL) + ATP (5 mM) posi-
tive control of inflammasome. Then, cells and supernatants were 
collected for performing different techniques at 1, 3, 6, 12, 24, 48, 
and 72 p.i. The number of cells used for the different techniques 
was: 6 × 106 cells/well for WB and ELISA, 3 × 106 cells for Flow 
Cytometry, and 3 × 105 cells for Immunofluorescence.
Flow cytometry
For the assessment of intracellular NO, cytoplasmic ROS (cROS), 
and mtROS, BMDM from each experimental condition were 
collected at 4°C and washed with PBS 2% FBS. First, cells were 
stained with APC labeled anti-CD11b and with FITC labeled 
anti-F4/80 for 20 min at 4°C. After that, BMDM were incubated 
with 20 µM DAF-FM diacetate probe for 30 min at 37°C for NO 
detection; 20 µM H2DCFDA probe for 20 min at 37°C for cROS 
detection; or 5 µM of a MitoSOX TM Red probe 20 min at 37°C 
for mtROS detection. Finally, these cells were analyzed by FACS 
as described previously (29).
cytokine Determination
IL-10, IL-12p70, TNFα, IL-6, and IL-1β were measured in culture 
supernatants by ELISA sandwich following the manufacturer’s 
guidelines.
Western Blot
Cells were processed as previously described (29). Lysates were 
prepared by protein measurement using the Bradford micro-
technique (32). Membranes were incubated overnight at 4°C 
with primary rabbit and mouse monoclonal antibodies anti-
phospho-mTOR, anti-phospho-p70S6K, anti-phospho-4EBP1, 
anti-Arginase-I, anti-iNOS, anti-NLRP3, anti-IL-1β, anti-β-
actin, or anti-ATP-cytrate lyase. Then, sheets were incubated with 
antibodies anti-Rabbit (IRDye® 680RD Donkey anti-Rabbit) and 
anti-Mouse (IRDye® 680RD Donkey anti-Mouse IgG) for 1 h, at 
room temperature and in darkness. An Odyssey CLx Infrared 
Imaging System (LI-COR, Inc.) was used to detect the bands.
immunofluorescence
Bone marrow-derived macrophages were treated as described 
in the Section “Inhibitors and Stimulus Treatments,” and non-
internalized parasites were eliminated by performing washes with 
RPMI 24 h later. Parasite growth in BMDM was determined by 
counting the number of intracellular amastigotes using immu-
nofluorescence assays as described (33). For nuclear staining, 
coverslips were incubated with DAPI, before being washed and 
incubated in mounting media FluorSave overnight. The slides 
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were observed using an Olympus BX41 microscope (Olympus 
Corporation, Tokyo, Japan) and a Leica DMi8 microscope (Leica 
Microsystems). Images were processed with ImageJ software.
griess assay
Nitric oxide levels were obtained by measuring those of the stable 
end product (nitrites) with Griess reagent assay (34). Absorbance 
at 540 nm was measured by the Bio Rad microplate reader and 
optical density was converted to micro molar of nitrites using a 
standard curve of sodium nitrite.
arginase reaction
Arginase activity was measured in macrophage lysates as 
previously described (33, 35, 36). Cells were lysed with 100 µL 
of 1% Triton X-100 containing protease inhibitor cocktail and 
phosphatase inhibitor. Then after 30 min, lysates were prepared 
for protein measurement by using the Bradford micro-technique 
(32). The urea (produced by arginine hidrolysis) was measured 
at 540 nm. The results were expressed as micrograms of urea per 
microgram of protein.
statistics
Statistical analyses were performed using the Student’s t-test 
of GraphPad Prism software version 6.0 (GraphPad Software). 
Discrepancies with a value of p < 0.05 were considered significant.
resUlTs
T. cruzi infection induces mTOr  
activation in Macrophages
It has been previously demonstrated that the invasion of try-
pomastigotes is reduced in HeLa cells treated with the mTOR 
inhibitor rapamycin (37). However, this has not yet been explored 
for mTOR function in macrophages during T. cruzi infection 
(38). Therefore, we infected BMDM with T. cruzi trypomastigotes 
and evaluated mTOR activation by WB through phosphoryla-
tion of its substrates 4EBP1 and P70S6K. The mTOR activation 
was observed at 6 and 24  h postinfection (Figure  1A), and in 
addition, we evaluated mTOR activation in peritoneal cells from 
mice at 15 days postinfection. The peritoneal cells from infected 
mice revealed an increase in 4EBP1 and P70S6K phosphoryla-
tion compared to control cells from uninfected mice (Figure 1B), 
with these results indicating that mTOR is an important pathway 
induced by the parasite in macrophages.
mTOr activation in Macrophages  
is essential for Parasite replication
To determine if mTOR activation is important for parasite 
survival, we performed experiments by targeting this pathway at 
different levels. First, BMDM were treated with the mTOR inhibi-
tors rapamycin or PP242, or with Ly249002 (a PI3K inhibitor) or 
DMSO as control and incubated 90 min. Then, cells were washed 
and infected with T. cruzi trypomastigotes. The number of 
intracellular parasites was evaluated 72 h later by immunofluores-
cence. It was observed that pretreatment with rapamycin, PP242, 
and Ly294002 significantly reduced the number of parasites in 
BMDM (Figures  2A,C) and also in peritoneal infected cells 
compared to DMSO-treated and infected cells (Figure  2B). 
However, the number of parasites increased in IL-4 stimulated 
and infected cells, used as positive control of parasite replication 
(Figures 2A,B).
None of these treatments produced any cytotoxic effect on 
the cells according to cell viability measured by the release of 
LDH in the supernatants of these cultures (data not shown). The 
inhibitory effect of the drugs was not a consequence of its action 
on the trypomastigotes, since inhibitors were removed before 
incubation with parasites. In addition, it has been reported that 
pretreatment of parasites with rapamycin does not alter their 
infectivity in HeLa cells, even for high drug concentrations (37). 
Thus, our results indicate that the T. cruzi parasite activates the 
mTOR pathway in macrophages in order to promote its survival, 
since mTOR inhibitors control parasite replication.
Modulation of T. cruzi-induced 
Macrophage Polarization by rapamycin
It has been suggested that mTOR in macrophages enhances the 
expression of M2-associated cytokines (38–40). Moreover, the 
pharmacological inhibition of mTOR with rapamycin resulted 
in an inhibition of LPS induction of IL-10 mRNA and protein, 
but enhanced the pro-inflammatory cytokine TNFα production 
(41). Thus, to determine the role of mTOR in T. cruzi-induced 
cytokines and whether this could influence the survival of the 
parasite in macrophages, we performed experiments by incubat-
ing BMDM with rapamycin or DMSO as control for 90 min, then, 
cells were washed and infected with T. cruzi trypomastigotes. 
On evaluating IL-10 and IL-12 production 24 h later by ELISA, 
it was found that rapamycin pretreatment induced a switch in 
cytokine production in infected macrophages. Moreover, a rise 
in IL-12 but a reduction in IL-10 production were observed in 
rapamycin-pretreated and infected macrophages compared to 
DMSO control macrophages (Figures 3A,B). To achieve a better 
understanding about the mechanisms implicated in controlling 
the parasite in rapamycin-treated macrophages, we evaluated 
Arginase I and iNOS, which are hallmarks of the M1 or M2 acti-
vation profiles, respectively. BMDM were pretreated for 90 min 
with rapamycin or DMSO as control, after which, the cells were 
washed and infected with T. cruzi trypomastigotes and Arginase 
I and iNOS expression and activities were measured 24 h later. 
Arginase was slightly induced by the parasite whereas rapamycin 
pretreatment reduced its expression and activity (Figures 3C,D), 
correlating with a decreased IL-10 production (Figure  3A). 
Surprisingly iNOS expression was also reduced in rapamycin 
pretreated and infected macrophages (Figure 3E), as well as the 
nitrite production in culture supernatants (Figure  3F) and the 
frequency of NO producing cells (Figure 3G).
cytoplasmic rOs Production and iDO 
activity are not involved in Parasite 
control in rapamycin-Treated and 
infected Macrophages
It has been previously shown that the ROS resulting from the 
respiratory burst have an important role in T. cruzi control 
FigUre 1 | Trypanosoma cruzi infection induces mammalian target of rapamycin (mTOR) activation in macrophages. mTOR activation was determined by 
phosphorylation of mTORC1 substrates, p-4EBP1, and p-P70S6K using Western blot assays (WB). (a) Bone marrow-derived macrophage (BMDM) cultured in 
RPMI without stimulus and without infection were used as control (UI), and BMDM stimulated with LPS 1 µg/mL were used as positive control (LPS). BMDM were 
infected by adding T. cruzi trypomastigotes (1:5, cell:parasite ratio). Infected BMDM were obtained and analyzed at different times (1, 6, and 24 h). Left panel shows 
a representative experiment and right panel shown densitometry analysis using ImageJ software. Bars represent mean ± SD from three independent experiments. 
Protein loading was evaluated by β-Actin expression, *p < 0.05 and **p < 0.005 vs. UI. (B) Peritoneal macrophages (PM) from T. cruzi-infected Balb/c mice were 
obtained at 15 days postinfection (d.p.i.) and PM from uninfected Balb/c mice were used as control (UI). Left panel shows a representative experiment and right 
panel shows densitometry analysis using ImageJ software. Bars represent mean ± SD of three independent experiments. The protein loading was evaluated by  
ATP citrate lyase expression (*p < 0.05 and **p < 0.005 vs. UI).
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(42–44), but ROS may be involved in cellular signaling and pro-
liferation of this parasite (45). Nevertheless, on evaluating cROS 
production in rapamycin-treated and infected macrophages at 
different points after infection by FACS (using H2DCFDA, which 
measures cROS and mainly detects H2O2), we did not observe 
any differences in the frequency of the cROS producing mac-
rophages between rapamycin-treated and infected macrophages 
and DMSO-treated and infected macrophages at 6 or 24 h p.i. 
(Figure  4A) or 24  h p.i. (Figure  4B). However macrophages 
stimulated with LPS plus IFN-γ, used as a positive control of ROS 
production, revealed a high frequency of cROS producing cells 
(Figure 4A).
On the other hand, the enzyme indoleamine 2,3-dioxigenase 
(IDO) of the tryptophan catabolism is involved in inhibiting 
intracellular pathogen replication (46, 47); moreover, IDO 
activity is induced by inflammatory cytokines and is essential 
for limiting the parasite’s reproduction in macrophages since 
T. cruzi amastigotes are sensitive to the l-kynurenine downstream 
metabolites (48). In order to examine the effect of IDO activity 
on the regulation of parasite growth in vitro in our experimental 
system, BMDM were cultured in the presence or absence of 
1-methyl-d-tryptophan (1-MT), an IDO inhibitor, for 24 h, before 
being treated with rapamycin for 90 min and then infected with 
T. cruzi. After 24 h, the non-internalized parasites were eliminated 
through washes, and the intracellular parasites were counted by 
immunofluorescence 72  h later. IDO blockade with 1-MT was 
demonstrated to cause a strong stimulatory effect on intracellular 
parasite growth, as previously reported (48). However, 1-MT 
treatment did not reverse the effect of rapamycin (Figures 4B,C), 
indicating that IDO is not involved in limiting parasite growth in 
rapamycin-pretreated and infected macrophages.
mTOr inhibition alters the cytokine 
Balance of Macrophages toward  
a Pro-inflammatory Phenotype upon  
T. cruzi infection
We have shown that rapamycin pretreatment induced an increase 
in IL-12 and a corresponding reduction in IL-10 production in 
infected macrophages (Figures 3A,B). It has been reported that 
rapamycin differentially modulates both pro- and anti-inflamma-
tory cytokine production in macrophages in response to LPS such 
as TNF-α, IL-6, and IL-1β, among others (24, 25, 49). BMDM were 
pretreated for 90 min with rapamycin or DMSO as control. Then, 
cells were washed and infected with T. cruzi trypomastigotes and 
cytokine production was evaluated at different time points after 
infection. mTOR inhibition by rapamycin in BMDM infected 
with T. cruzi led to a strong upregulation of IL-12 production 
(Figures 3B and 5B). At the same time, the anti-inflammatory 
cytokine IL-10 was remarkably suppressed (Figures 3A and 5A), 
whereas, importantly, mTOR inhibition increased the produc-
tion of the pro-inflammatory cytokines IL-6, TNF-α, and IL-1β 
(Figures 5C–E respectively). These results indicate that mTOR 
inhibition alters the cytokine balance of macrophages toward a 
pro-inflammatory phenotype upon T. cruzi infection.
rapamycin induces nlrP3 expression in 
T. cruzi-infected Macrophages, Which is 
relevant in the control of Parasite 
replication
It has been shown that NLRP3 is involved in the antiparasitic 
response against T. cruzi, but the mechanisms involved are 
FigUre 2 | Mammalian target of rapamycin (mTOR) activation in macrophages is essential for parasite replication. (a) Bone marrow-derived macrophage (BMDM) 
and (B) peritoneal macrophages (PM) from Balb/c mice were pretreated with DMSO as control or with different mTOR inhibitors: rapamycin (50 or 100 nM), PP242 
(40 or 80 nM), and LY294002 (10 or 50 nM) during 90 min. Cells were washed and then were infected with Trypanosoma cruzi trypomastigotes (1:5, cell:parasite 
ratio) during 24 h. Besides, BMDM (A) or PM (B) without inhibitors pretreatment were stimulated with IL-4 (80 ng/mL) and infected with T. cruzi trypomastigotes  
(1:5, cell:parasite ratio) during 24 h as positive control of infection. After that, non-internalized parasites were removed and 72 h later intracellular amastigotes were 
counted by indirect immunofluorescence. Parasite replication was expressed as number of parasites per 100 cells, quantified by ImageJ software. Bars represent 
mean ± SD from three independent experiments (***p < 0.001 vs. DMSO). (c) A representative image from DMSO or rapamycin pretreated BMDM shown cell 
nucleus stained with DAPI and parasites in green. Inserts show an area from the image (arrowhead) at higher magnification, indicating infected macrophages.
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known to depend on the experimental design employed (50). 
Here, we evaluated NLRP3 expression and IL-1β production in 
rapamycin pretreated and infected macrophages. Briefly, BMDM 
were pretreated for 90 min with rapamycin or DMSO as control 
and cells were washed and infected with T. cruzi trypomastigotes. 
Cell lysates and supernatants were collected 6 h p.i., and NLRP3 
expression and IL-1β production were measured by wild type. 
We observed that mTOR inhibition by rapamycin in T. cruzi-
infected BMDM led to a potent upregulation of NLRP3 and an 
increase in IL-lβ production (Figure 6A), with BMDM stimulated 
with ATP plus LPS serving as a positive control of inflammasome 
activation.
Then, to study the relevance of NLRP3 activation during 
mTOR inhibition in infected macrophages, we obtained 
BMDM from NLRP3 KO or wild-type (WT) mice and pre-
treated them with rapamycin or DMSO for 90 min. Then, cells 
were infected and T. cruzi intracellular replication was meas-
ured by immunofluorescence. In agreement with Figure 2 and 
Figure S2 in Supplementary Material, a reduction in parasite 
growth in rapamycin pretreated and infected BMDM from WT 
was observed. However, rapamycin pretreated and infected 
BMDM from NLRP3 KO showed a strong increase in parasite 
replication, which was even more robust than that observed 
in IL-4 stimulated BMDM used as control (Figure  6B). 
Representative images from DMSO or rapamycin treated and 
infected WT BMDM (Figures  6C) and NLRP3 KO BMDM 
are shown in Figure 6D. In addition, in rapamycin pretreated 
and infected BMDM from TNFα-R KO and IL-6 KO mice 
there was an increase in parasite replication compared with 
rapamycin-pretreated and infected BMDM from WT mice. 
However, this effect was less evident than in the BMDM from 
NLRP3 KO mice (Figure 6B and Figure S3 in Supplementary 
Material).
mtrOs Production is important in 
controlling Parasite replication during 
mTOr inhibition in T. cruzi-infected 
Macrophages
It has been previously shown that mitochondria participate in 
inflammasome activation (51). The NLRP3 inflammasome is the 
best characterized among various inflammasome complexes, 
FigUre 3 | Continued
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FigUre 4 | Decreased Trypanosoma cruzi replication by mammalian target of rapamycin inhibition was independent of cytoplasmic ROS and IDO. (a) Bone 
marrow-derived macrophages (BMDM) from C57BL/6 mice were pretreated with DMSO as control or with rapamycin (100 nM) during 90 min. After pretreatment 
cells were washed and uninfected (UI) or T. cruzi-infected (T. cruzi) (1:5, cell:parasite ratio) were cultured at different times and then processed for the experiments. 
Besides, BMDM were stimulated with LPS + IFNγ (1 µg/mL + 100 ng/mL), during 24 h as positive control. BMDM at 6 and 24 h postinfection were stained with 
anti-F480 (PE) and anti-CD11b (APC) mAbs. Then, cells were incubated with 20 µM H2DCFDA probe, 20 min at 37°C for intracellular reactive oxygen species (ROS) 
detection. Bars represent mean ± SD of from three independent experiments (ns, no significant difference vs. DMSO). (B–c) Parasite replication in BMDM from 
C57BL6 mice pretreated with DMSO as control, or with Rapamycin (RAPA: 100 nM) during 90 min, or with 1-methyl tryptophan (1-MT: 100 µM; 24 h) or with 1-MT 
(24 h) + RAPA (90 min). After pretreatment BMDM were washed and then infected with T. cruzi trypomastigotes (1:5, cell:parasite ratio) during 24 h. Besides, BMDM 
without inhibitors pretreatment, were stimulated with LPS + IFNγ (1 µg/mL + 100 ng/mL), during 24 h as positive control. After that, non-internalized parasites were 
removed and 72 h later intracellular amastigotes were counted by indirect immunofluorescence. (B) Intracellular replication of T. cruzi is expressed as number of 
parasites per 100 cells, quantified by ImageJ software and represent mean ± SD from three independent experiments (*p < 0.05 and **p < 0.005, vs. DMSO).  
(c) A representative image shows cell nucleus stained with DAPI and parasites in green. Inserts show an area from the image (arrowhead) at higher magnification, 
indicating infected macrophages.
FigUre 3 | Modulation of Trypanosoma cruzi-induced macrophage polarization by rapamycin. Macrophage polarization was evaluated through cytokine 
production, Arginase I, and iNOS expression and activity. Bone marrow-derived macrophage (BMDM) from Balb/c mice were pretreated with DMSO as control,  
or with rapamycin (100 nM) during 90 min. After pretreatment cells were washed and uninfected (UI) or T. cruzi-infected (T. cruzi) (1:5, cell:parasite ratio) BMDM  
were cultured during 24 h and then processed for the different experiment. (a) IL-10 and (B) IL-12p70 production were measured by ELISA sandwich-assays. 
Besides, BMDM with or without rapamycin pretreatment were stimulated with LPS 1 µg/mL as positive control (LPS) during 24 h. Arginase I (c) and iNOS  
(e) expression from cellular lysates were performed by western blot at 24 h postinfection, using as loading control β-actin. Besides, BMDM were stimulated with  
IL-4 (80 ng/mL) or LPS (1 µg/mL) + IFNγ (100 ng/mL) during 24 h as positive controls for Arginase-I (C) or iNOS (E) expression, respectively. Upper panel shows 
densitometry analysis using ImageJ software. Bars represent mean ± SD from three independent experiments (***p < 0.001 vs. DMSO). Bottom panel shows  
a representative experiment. (D) Arginase activity was determined by urea production assay 24 h p.i. (F) iNOS activity was evaluate by Griess reaction on 
supernatants 24 h p.i. (g) Besides, iNOS activity was determined by FACS. BMDM were stained with anti-F480 (PE) and anti-CD11b (APC) and then incubated  
with DAF-FM-DA probe (20 µM, FITC), 30 min at 37°C for intracellular NO detection. Bars represent mean ± SD from three independent experiments (*p < 0.05, 
**p < 0.005, and ***p < 0.001 vs. DMSO; ns, no significant difference vs. DMSO).
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FigUre 5 | Mammalian target of rapamycin inhibition alters cytokine balance in macrophages toward a pro-inflammatory phenotype upon Trypanosoma cruzi 
infection. Bone marrow-derived macrophages (BMDMs) from C57BL/6 mice were pretreated with DMSO as control or with rapamycin (100 nM) during 90 min. After 
pretreatment, BMDM uninfected or infected with T. cruzi trypomastigotes (1:5, cell:parasite ratio) were cultured at different times. At 12, 18, and 24 h postinfection, 
supernatants were collected and processed to determine the IL-10 (a), IL-12p70 (B), IL-6 (c), TNFα (D), and IL-1β (e) production by ELISA Sandwich. Besides, 
supernatants from BMDM stimulated with IL-4 (80 ng/mL), or with LPS (1 µg/mL) + IFNγ (100 ng/mL), or with LPS (1 µg/mL) + ATP (5 mM) during 24 h were used 
as positive controls. Bars panels represent mean ± SD from three independent assays (*p < 0.05, **p < 0.005, and ***p < 0.001 vs. DMSO).
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with its activation depending on different stress signals, includ-
ing ROS production promoted by mitochondrial dysfunction 
(51). Thus, we evaluated mtROS production in rapamycin 
treated and infected BMDM at different points after infection 
using MitoSOX, which measures mtROS and mainly detects 
superoxide radical. We found a significant increase in mtROS 
production in rapamycin-pretreated and infected BMDM, with 
increased levels of mtROS being observed in ATP plus LPS-
stimulated BMDM, used as positive control (Figure 7A). Then, 
to evaluate whether mtROS is relevant for controlling parasite 
replication, BMDM from WT mice were pretreated with rapa-
mycin, DPI (NADPH oxidase inhibitor), rapamycin + DPI, or 
DMSO before being infected, and the parasite load was studied 
by immunofluorescence. It was observed that BMDM incubated 
with rapamycin plus DPI had a significantly higher parasite 
load compared to rapamycin-pretreated BMDM (Figure  7B), 
with a representative image from DMSO, rapamycin, DPI, and 
rapamycin plus DPI treated and infected BMDM being shown 
in Figure 7C. Additionally, we have observed that DPI inhibits 
mtROS production induced by rapamycin pretreatment and T. 
cruzi infection, Figure S4 in Supplementary Material. This may 
indicate that mtROS would participate in the control of T. cruzi 
replication. These findings strongly suggest that mTOR inhibi-
tion during T. cruzi infection in BMDM induces inflammasome 
NLRP3 activation and mtROS production, which controls 
parasite survival.
DiscUssiOn
In order to control the T. cruzi infection, it is necessary that 
cytokine-mediated macrophage activation leads to intracellular 
killing of the parasite. Moreover, M1 polarization is closely related 
to parasite removal, whereas M2 polarization can be effective in 
countering the development of an oxidative and inflammatory 
pathology in Chagas disease (35, 36, 52).
As the protein mTOR is a critical regulator of the host cell 
metabolism, it is a logical target to be manipulated by invasive 
pathogens such as T. cruzi. In this investigation, we examined the 
role of the mTOR pathway in macrophage polarization induced 
by T. cruzi and we observed that mTOR is activated in vitro by the 
parasite in BMDM. In addition, peritoneal cells obtained from 
infected mice showed an increase in mTOR activation compared 
to those from uninfected mice. These results clearly indicate 
that mTOR is an important pathway induced by the parasite in 
macrophages considering that its inhibition during infection 
shifts these macrophages to an M1-like inflammatory profile by 
reducing IL-10 and arginase activity and expression. Rapamycin 
pretreated and infected macrophages revealed an activation of 
the NLRP3 inflammasome and an increased production of IL-12, 
IL-6, TNF-α, IL-1β, and mtROS. Thus, these macrophages have 
an increased ability to limit parasite replication, which was clearly 
demonstrated using three different inhibitors of the mTOR path-
way (rapamycin, PP242, and LY249002).
FigUre 6 | Continued
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The selective deletion of signals through mTORC1 in mac-
rophages promotes M1 cytokines (53), whereas deletion of 
signals through mTORC2 inhibits the generation of M2 while 
maintaining intact the generation of M1 (54). In TLR-induced pro-
inflammatory cytokine production, the role of the TSC-mTOR 
pathway is still unclear. It was reported that in TSC2-deficient 
FigUre 7 | Mitochondrial ROS (mtROS) production is important to control parasite replication during mammalian target of rapamycin (mTOR) inhibition in 
Trypanosoma cruzi-infected macrophages. (a) Bone marrow-derived macrophage (BMDM) from C57BL/6 mice pretreated with DMSO as control or with rapamycin 
(100 nM) during 90 min. After pretreatment cells were washed and uninfected or infected T. cruzi BMDM (1:5, cell:parasite ratio) were cultured at 3 and 6 h. Besides, 
BMDM without rapamycin pretreatment were stimulated with LPS + ATP (1 µg/mL and 5 mM) during 3 and 6 h. At indicates times postinfection (p.i.), BMDM were 
stained with anti-F480 (FITC) and anti-CD11b (APC) mAbs. Then, cells were incubated with 5 µM MitoSOX probe (PE) 15 min at 37°C and analyzed by Flow 
cytometry. Bars display mean fluorescence intensity (MFI) of mtROS on F4/80+ CD11b+ gated populations. Experiments were repeated three times with similar 
results being obtained and are expressed as mean ± SD (*p < 0.05 and **p < 0.005 vs. DMSO). A representative histogram of at least three independent 
experiments is shown. (B) Parasite replication in BMDM from C57BL6 mice pretreated with DMSO as control (24 h) rapamycin (100 nM, 90 min), with DPI (20 µm, 
3 h) or with DPI + rapamycin. After pretreatment, cells were washed and infected with T. cruzi trypomastigotes (1:5, cell:parasite ratio) during 24 h. Besides, BMDM 
without inhibitors pretreatment, were stimulated with LPS (1 µg/mL) + IFNγ (100 ng/mL) or with IL-4 (80 ng/mL) and infected with T. cruzi trypomastigotes  
(1:5, cell:parasite ratio) during 24 h as controls. After that, non-internalized parasite were removed and 72 h later intracellular amastigotes were counted by indirect 
immunofluorescence. Intracellular replication of T. cruzi is expressed as number of parasites per 100 cells, quantified by ImageJ software and represent mean ± SD 
from three independent experiments (*p < 0.05; vs. rapamycin). (c) A representative image from DMSO, rapamycin, DPI, rapamycin + DPI pretreated BMDM, show 
cell nucleus stained with DAPI and parasites in green. Inserts show an area from the image (arrowhead) at higher magnification, indicating infected macrophages.
FigUre 6 | Rapamycin induces NLRP3 activation in Trypanosoma cruzi-infected macrophages, a relevant event to control parasite replication. (a) NLRP3 activation 
was determined by NLRP3 expression (upper panel) and cleaved IL-1β release (bottom panel) using western blot assays (WB). Bone marrow-derived macrophages 
(BMDMs) from C57BL/6 mice were pretreated with DMSO as control or with rapamycin (100 nM) during 90 min. After rapamycin pretreatment cells were washed 
and uninfected (UI) or T. cruzi-infected BMDM (T. cruzi) (1:5, cell:parasite ratio) were cultured during 6 h. Besides, BMDM were stimulated with LPS (1 µg/mL) + ATP 
(5 mM) as positive control. Then, cell lysates and supernatants were processed for WB. A representative experiment of three independent experiments is shown. 
The protein loading for NLRP3 and IL-1β was evaluated by β-Actin expression and by Ponceau staining, respectively. Densitometry analysis from cell lysates was 
performed by ImageJ software (*p < 0.05 and **p < 0.005 vs. DMSO). (B) Parasite replication in BMDM from wild-type (WT), TNFαR KO, IL-6 KO, and NLRP3 KO 
mice. BMDM were pretreated with DMSO as control or with rapamycin (100 nM) during 90 min. After pretreatment, cells were washed and infected with T. cruzi 
trypomastigotes (1:5, cell:parasite ratio) during 24 h. Besides, WT BMDM without rapamycin pretreatment were stimulated with LPS (1 µg/mL) + IFNγ (100 ng/mL) 
and infected with T. cruzi trypomastigotes (1:5, cell:parasite ratio) during 24 h as negative control of parasite replication. On the other hand, WT BMDM without 
rapamycin pretreatment were stimulated with IL-4 (80 ng/mL) and infected with T. cruzi trypomastigotes (1:5, cell:parasite ratio) during 24 h as positive control of 
parasite replication. After that, non-internalized parasite were removed, and 72 h later, intracellular amastigotes were counted by indirect immunofluorescence. 
Intracellular replication of T. cruzi is expressed as number of parasites per 100 cells, quantified by ImageJ software and represent mean ± SD from three 
independent experiments (*p < 0.05, **p < 0.005, and ***p < 0.001 vs. DMSO). A representative image from WT (c) and NLRP3 KO (D) BMDM show cell  
nucleus stained with DAPI and parasites in green. Insert show an area from the image (arrowhead) at higher magnification, indicating infected macrophages.
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MEFs, the pro-inflammatory responses are reduced as a result 
of impaired IKK activation and NF-κB translation to the nuclei 
(54). Nevertheless, other studies have found that rapamycin 
treatment enhances the IL-12 production in myeloid DCs by 
stimulating NF-κB activation, but prevents IL-12 production in 
bone marrow-derived DCs and monocyte-derived ones (40, 55). 
Moreover, TSC1-deficient macrophages produce elevated pro- 
inflammatory cytokines in response to an LPS stimulation, 
such as TNF-α, IL-12, and IL-6 (18, 19, 24). The reason for this 
apparent inconsistency is still unknown, but possibly originates 
from the different cell types or the length of mTOR inhibition 
with rapamycin. Here, we found that mTOR inhibition by rapa-
mycin (90 min) in BMDM infected with T. cruzi led to a potent 
upregulation of IL-12 production, whereas the anti-inflammatory 
cytokine IL-10 was notably suppressed. Furthermore, mTOR 
inhibition increased the production of the pro-inflammatory 
cytokines IL-6 and TNF-α. These results indicate that mTOR 
inhibition alters the cytokine balance of macrophages toward a 
pro-inflammatory phenotype upon T. cruzi infection.
The role of the mTOR pathway in the regulation of IL-1β expres-
sion has been examined in both mouse and human macrophages 
(38, 56). In addition, other authors have used TSC1-deficient 
macrophages and macrophage cell lines to study the involvement 
of TSC1 in pro-inflammatory cytokine IL-1β expression and 
investigated the associated molecular mechanism. They reported 
that at the level of both the mRNA and protein, the LPS-induced 
pro-IL-1β synthesis was significantly downregulated in TSC1-
deficient macrophages, by extended rapamycin (48 h) treatment 
or mTOR deletion (18). In contrast, we found that mTOR inhibi-
tion by rapamycin (90 min) in T. cruzi-infected BMDM led to a 
potent upregulation of IL-1β production. However, it is possible 
that differences in exposure time of the macrophages to rapamy-
cin, was crucial in determining the outcome.
Deletion of Akt1 promotes upregulation of inducible NO syn-
thase and IL-12 (M1 activation) and enhances bacteria clearance 
(57, 58). We observed that pretreatment with mTOR inhibitors 
(rapamycin, PP242) and PI3K inhibitor (Ly294002) significantly 
reduced the number of parasites in BMDM and in peritoneal 
infected cells compared to DMSO-treated and infected cells. Also, 
we found that a short period of mTOR inhibition previous to 
infection induced an inflammatory profile in these macrophages 
similar to an M1 polarization without iNOS expression. It is also 
possible that mTOR inhibition also modifies T. cruzi invasion in 
BMDM, since this was demonstrated through the inhibition of 
PI3K (59, 60).
Importantly, macrophage alternative (or M2) activation is 
induced by signaling through the IL-4R via STAT6. Related to 
this, TSC1-deficient macrophages have been found to fail to 
alternatively activate in response to IL-4, reflecting the fact that 
pronounced mTORC1 signaling is a strong negative regulator 
of alternative activation (61, 62). This was not due to effects on 
STAT6 phosphorylation, but rather to feedback inhibition of Akt 
phosphorylation through effects on the insulin receptor substrate 
2, which is also engaged by IL-4R signaling (18, 62). Interestingly, 
in TSC1-deficient macrophages, low-dose rapamycin (which 
preferentially inhibits mTORC1 but not mTORC2) allows an 
alternative activation in response to IL-4. However, recent work 
using higher concentrations of rapamycin (which also inhibits 
mTORC2), Torin (which inhibits both mTORC1 and mTORC2), 
and Rictor deficient macrophages has revealed that mTORC2 is 
critical for alternative activation (54, 63). Thus, mTORC2 acts 
in parallel with pSTAT6 to promote an alternative activation, in 
part by cooperating in events that lead to expression of IRF4 (63). 
In our present investigation, rapamycin induced not only a 
decrease in the activity and expression of arginase and IL-10 pro-
duction in T. cruzi-infected BMDM but also produced a decrease 
in iNOS expression and activity. Moreover, although cROS was 
not induced, rapamycin induced mtROS and IL-1β production 
along with pro-inflammatory cytokines such as IL-12, IL-6, 
and TNF-α.
The NLRs are part of the response to T. cruzi, as first reported 
for NOD1 (27). Although KO animals for this receptor have a 
higher parasite burden and mortality than WT, they are still 
capable of producing cytokines at systemic level, suggesting that 
other NLRs may also contribute to resistance against this parasite. 
NLRP3 is activated in response to lysosomal damage generated by 
the escape of protozoan from the parasitophora vacuole, but this 
is independent of the K+ flow and ROS generation (26). These 
studies showed that NO production is eliminated in primary 
macrophages from NLRP3 KO T. cruzi Y strain-infected mice. 
However, some authors (64) argue that this phenomenon is 
dependent on both IL-1β and IL-1R, while others have postulated 
that this is independent of these molecules (50). Nevertheless, 
these results emphasize the complexity of the antiparasitic 
response orchestrated by the NLRP3 inflammasome together 
with other innate receptors and reflected in various microbicidal 
mechanisms assembled against T. cruzi (51, 65). In our study, 
rapamycin pretreatment in T. cruzi-infected BMDM induced 
NLRP3 expression, mtROS and IL-1β production, but not cROS 
or NO production.
Several studies have indicated that cROS is a necessary sec-
ondary messenger in order to achieve signaling caspase-1/ASC 
inflammasome activation (66, 67), but this was demonstrated 
for a feedback cycle of IL-1β signaling of cROS activation in 
T. cruzi-infected macrophages (50), with the molecular mecha-
nisms involved in cROS production induced by IL-1β remaining 
to be clarified. In previous investigations, IL-1β was reported 
to promote phospholipase A2, thereby stimulating the release 
of arachidonic acid. However, since arachidonic acid is able to 
activate NADPH oxidase to afford superoxide, it is a possibility 
that this fatty acid serves as an intermediate in the IL-1β-induced 
activation of the enzymes, thus resulting in the production of 
ROS (67, 68). In our study, we demonstrated that rapamycin 
pretreatment in T. cruzi-infected macrophages induces mtROS 
production, which is involved in the control of T. cruzi replica-
tion, since an inhibitor of NADPH oxidase (DPI) partially 
reverses the effect of rapamycin. Certainly DPI is as potent as 
rotenone in inhibiting the production of superoxide and H2O2 by 
mitochondrial respiration.
It is important to emphasize that we cannot exclude the 
possible implication of mTOR inhibition in the limitation of 
some nutrients relevant for T. cruzi proliferation within BMDM, 
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thus potentiating microbicidal effect of mtROS. This would be 
supported by the effect of partial inhibition produced by DPI 
treatment. In addition, it would be interesting to study the 
mechanism of mtROS inhibition by DPI and its effect on T. cruzi 
replication. It would be possible that changes in macrophages 
metabolism lead them to a metabolic program mediated by 
oxidative phosphorylation in detriment of glycolysis that is 
characteristic of M1 macrophages (69), since DPI influences 
mitochondrial respiration. However, the relevance of mtROS 
in controlling the intracellular growth of a microorganism has 
already been demonstrated in macrophages treated with met-
formin and infected with M. tuberculosis. In fact, metformin is 
an activator of the AMP-activated protein kinase, which has an 
important role in cellular energy homeostasis. Subsequently, our 
results indicate that the modulation of macrophage metabolism 
may be a new therapeutic tool in the control of intracellular 
infections (70).
In summary, the relevance of this study lies in the fact that 
treatment with rapamycin prior to macrophage T. cruzi infec-
tion controlled the intracellular growth of the parasite through 
inflammasome NLRP3 expression and the production of mtROS. 
In contrast, the iNOS and IDO enzymes were not involved. Thus, 
induction of mtROS may be relevant in the control of pathogen 
infections residing in macrophages.
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